NEW YORK — BioView and Ruby Nanomed said on Thursday that they have partnered on the development of a circulating tumor cell (CTC) analysis technology for clinical use.
Under the terms of the alliance, the companies will integrate BioView's Duet imaging system with Ruby Nanomed's Rubychip microfluidic device for CTC isolation, enabling the automatic classification of cancer cells within the device with the goal of facilitating patient monitoring and stratification. The work is being funded by Spanish nonprofit La Caixa Foundation.
Additional terms were not disclosed.